This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove DEA Remove Legalization Remove Medical Evaluation Remove State Laws
article thumbnail

Document: Barr Responses To QFR’s: CLR Digs Out The Relevant Q’s & A’s

Cannabis Law Report

JANUARY 30, 2019

To expand the number of manufacturers, the Drug Enforcement Administration (DEA) submitted a notice in the Federal Register on August 11, 2016, soliciting applications for licenses to manufacture marijuana for research purposes. Both DOJ and HHS agreed to conduct a medical and scientific evaluation of CBD independent of marijuana in 2015.

Research and Development 63
Research and Development DEA CBD Law 63
article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

MARCH 25, 2019

The Attorney General forwards the request to the Health and Human Services Secretary and requests a scientific and medical evaluation and recommendation, as specified by 23 USC 811(b-c). At the present time, state medical and recreational legalization have no impact on federal drug control laws.

Banking 45
Banking Law Marijuana State Laws 45
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024